70 related articles for article (PubMed ID: 20130878)
41. Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
Br J Cancer; 1998; 77(1):153-8. PubMed ID: 9459161
[TBL] [Abstract][Full Text] [Related]
42. [A combination study of S-1 and docetaxel in patients with head and neck cancer].
Ito H; Yoshida T; Tokashiki R; Shimizu A; Hiramatsu H; Tsukahara K; Funato N
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():160-2. PubMed ID: 16897994
[TBL] [Abstract][Full Text] [Related]
43. Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
Kraut EH; Rhoades C; Zhang Y; Cheng H; Aimiumu J; Chen P; Lang J; Young DC; Agrawal A; Dancey J; Chan KK; Grever MR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):579-86. PubMed ID: 20490801
[TBL] [Abstract][Full Text] [Related]
44. A preclinical model for experimental chemotherapy of human head and neck cancer.
Sommer K; Peters SO; Robins IH; Raap M; Wiedemann GJ; Remmert S; Sieg P; Bittner C; Feyerabend T
Int J Oncol; 2001 Jun; 18(6):1145-9. PubMed ID: 11351243
[TBL] [Abstract][Full Text] [Related]
45. Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study).
Barnadas A; Mesía R; Majem M; Galiana R; López-Pousa A; de Vega JM; Margelí M; Valentí V; Anglada L; Lloansí A; Arellano A
Clin Transl Oncol; 2011 Apr; 13(4):254-60. PubMed ID: 21493186
[TBL] [Abstract][Full Text] [Related]
46. [Weekly docetaxel treatment for head and neck cancer].
Okamoto H; Yane K; Yamanaka T; Fukuda T; Hosoi H
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1915-8. PubMed ID: 16282726
[TBL] [Abstract][Full Text] [Related]
47. Safe dose reduction of steroid pre-medication for docetaxel in head and neck neoplasm treatment.
Chen NX; Zhao FF; Yan F; Zhang XX
Acta Otolaryngol; 2016; 136(2):177-80. PubMed ID: 26472564
[TBL] [Abstract][Full Text] [Related]
48. Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer.
Culine S; Terret C; Cupissol D; Romieu G; Fabbro M; Pouessel D; Droz JP; Gourgou S
J Geriatr Oncol; 2013 Apr; 4(2):122-7. PubMed ID: 24071537
[TBL] [Abstract][Full Text] [Related]
49. Complete response to weekly carboplatin-docetaxel chemotherapy in a 91-year-old woman with anaplastic thyroid cancer.
Koussis H; Giorgi CA; Di Liso E; Carlucci MC; Fassina A; Marioni G; Conte PF
Am J Otolaryngol; 2015; 36(2):268-72. PubMed ID: 25681954
[TBL] [Abstract][Full Text] [Related]
50. A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles.
Sorbe B; Graflund M; Nygren L; Horvath G
Oncol Lett; 2013 Apr; 5(4):1140-1148. PubMed ID: 23599753
[TBL] [Abstract][Full Text] [Related]
51. [Three cases of adenocarcinoma of the head and neck maintaining QOL by administration of docetaxel].
Shimane T; Mori T; Ono T; Egawa S; Furuta A; Ikeda K; Kamakazu K; Kobayashi S; Sanbe T; Suzaki H
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2897-900. PubMed ID: 21160265
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma.
Casper ES; Schwartz GM; Leung D; Sugarman A; Bertino JR
Sarcoma; 1999; 3(2):121-7. PubMed ID: 18521274
[TBL] [Abstract][Full Text] [Related]
53. Intradermal carboplatin and ifosfamide extravasation in the mouse.
Marnocha RS; Hutson PR
Cancer; 1992 Aug; 70(4):850-3. PubMed ID: 1643617
[TBL] [Abstract][Full Text] [Related]
54. Hyponatraemia secondary to administration of ifosfamide.
Izquierdo R; Leinung M
Eur J Cancer; 1993; 29A(14):2072-3. PubMed ID: 8280505
[No Abstract] [Full Text] [Related]
55. Radiation Recall Myositis After Carboplatin/Docetaxel Chemotherapy.
Chao HH; Feld EK; Narayan V; Sebro R; Jones JA
Pract Radiat Oncol; 2020; 10(1):e50-e52. PubMed ID: 31356886
[No Abstract] [Full Text] [Related]
56. Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93).
Rathore R; Birnbaum A; Rathore B; DiPetrillo T; Kennedy T; Ready N
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1013-7. PubMed ID: 20130878
[TBL] [Abstract][Full Text] [Related]
57. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
58. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
[TBL] [Abstract][Full Text] [Related]
59. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
[TBL] [Abstract][Full Text] [Related]
60. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
